What we have learned from the myriad trials

What We Have Learned from the Myriad Trials
First Online:
Received:
Accepted:

Keywords

Memantine AChE Inhibitor Last Observation Carry Forward Mild Patient Disease Assessment Scale Cognitive Subscale 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Wilcock GK, Black SE, Hendrix SB, Zavitz KH, Swabb EA, Laughlin MA, Tarenflurbil Phase 11 Study investigators. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer’s disease: a randomised phase 11 trial. Lancet Neurol. 2008 Jun;7(6):483–493.PubMedCrossRefGoogle Scholar
  2. 2.
    Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189–198.PubMedCrossRefGoogle Scholar
  3. 3.
    Green R, Schneider L, Hendrix S, Zavitz K, Swabb E. “03-04-01: Safety and efficacy of tarenflurbil in subjects with mild Alzheimer’s disease: Results from an 18-month multi-center phase 3 trial.” Alzheimer Dement 2008; 4, T165 (abstr).CrossRefGoogle Scholar
  4. 4.
    Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. Am J Psychiatry 1984; 141:1356–1364.PubMedGoogle Scholar
  5. 5.
    Mohs RC, Knopman D, Petersen RC, et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer’s disease assessment scale that broaden its scope. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11(suppl 2): S13–21.PubMedGoogle Scholar
  6. 6.
    Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11(suppl 2): S33–39.PubMedCrossRefGoogle Scholar
  7. 7.
    Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry 1982; 140: 566–572.PubMedCrossRefGoogle Scholar
  8. 8.
    Jackson M, Hendrix S, Zavitz K, Green R, Schneider L, Swabb E. P4–376: A phase 3 multicenter trial of tarenflurbil in subjects with mild dementia of the Alzheimer’s type (Act-Earli-AD): Rationale and methodology. Alzheimer Dement 2008, 4, T784 (abstr).CrossRefGoogle Scholar
  9. 9.
    Hendrix S, Gutin A, Zavitz K, Carron G, Laughlin M, Horton S. Modification of the staggered start and randomized withdrawal clinical trial designs: toward a practical demonstration of disease modification in Alzheimer’s disease (AD). Alzheimer Dement 2007; 3:S160 (abstr).CrossRefGoogle Scholar
  10. 10.
    Chuang-Stein C. Seize the opportunities Pharmaceutical Statistics 2004; 3, 157–159Google Scholar
  11. 11.
    Pocock S, White I. Trials stopped early: too good to be true? Lancet 1999; 353(9157):943–944.PubMedCrossRefGoogle Scholar

Copyright information

© Serdi and Springer Verlag France 2009

Authors and Affiliations

  1. 1.Pentara CorporationSalt Lake CityUSA

Personalised recommendations